Literature DB >> 7698194

Different mechanism of tachykinin NK2 receptor blockade by SR 48968 and MEN 10,627 in the guinea-pig isolated gallbladder and colon.

R Patacchini1, R De Giorgio, A Giachetti, C A Maggi.   

Abstract

The mechanism of action of the tachykinin NK2 receptor antagonists, SR 48968 ((S)-N-methyl-N[4-acetylamino-4-phenyl-piperidino)-2-(3,4- dichlorophenyl)butyl]benzamide) and MEN 10,627 (cyclo[(Met-Asp-Trp-Phe-Dap-Leu) cyclo (2 beta-5 beta)]), was compared in the guinea-pig isolated gallbladder and circular muscle of proximal colon by using neurokinin A and [beta Ala8]neurokinin A-(4-10) as agonists. The experiments performed with colon were in the presence of the tachykinin NK1 receptor-selective antagonist, (+/-)-CP-96,345 ([2-(diphenylmethyl)-N-[(2-methoxyphenyl)-methyl]-1- azabicyclo[2,2,2]octan-3-amine]). SR 48968 caused an insurmountable antagonism of tachykinin NK2 receptor-mediated contraction in both preparations; its blockade was essentially irreversible, since it was not reversed by washout (up to 2 h) and was increased by prolonging the incubation from 15 to 120 min. In contrast, MEN 10,627 produced simple competitive antagonism, which was time-independent and fully reversible in both preparations. In both preparations, the simultaneous administration of SR 48968 and MEN 10,627 produced an intermediate antagonism of the responses to the agonists, as compared to the antagonism produced by each antagonist alone. The present results are discussed in the light of the reported interaction of SR 48968 with tachykinin NK2 receptors at a recognition epitope distinct from that of agonist(s).

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7698194     DOI: 10.1016/0014-2999(94)90271-2

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  1 in total

1.  Tachykinin-induced contraction of the guinea-pig isolated oesophageal mucosa is mediated by NK(2) receptors.

Authors:  K P Kerr; B Thai; I M Coupar
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.